Loading organizations...

§ Private Profile · San Diego, CA, USA
Clinical-stage biotech develops mRNA targeting & editing therapeutics for genetic, cardiometabolic, and CNS disorders.
San Diego, California-based ADARx Pharmaceuticals is a clinical-stage biotechnology company developing genetic medicine therapeutics focused on messenger RNA targeting and editing. The organization utilizes proprietary adenosine deaminase acting on RNA technology to precisely correct single point mutations at the mRNA level, restoring the production of functional proteins to treat genetic, cardiometabolic, and central nervous system disorders. To support its expanding clinical pipeline, the enterprise has raised $352.5 million in total venture funding, which includes a highly oversubscribed $200 million Series C financing round closed in August 2023. The company is backed by prominent institutional investors such as Bain Capital Life Sciences, BlackRock, and OrbiMed, and has established a strategic co-development partnership with AbbVie to advance specific therapeutic applications. ADARx Pharmaceuticals was originally founded in 2019 by Dr. Zhen Li and a team of scientific colleagues.
ADARx Pharmaceuticals has raised $321.0M across 3 funding rounds.
ADARx Pharmaceuticals has raised $321.0M in total across 3 funding rounds.
ADARx Pharmaceuticals has raised $321.0M across 3 funding rounds. Most recently, it raised $200.0M Series C in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2023 | $200M Series C | Ricky SUN, Chen YU | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, OrbiMed, SR ONE, Third Rock Ventures, Ascenta Capital, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Lilly Asia Ventures, Redmile Group, T. Rowe Price Associates, Venrock, Vivo Capital | Announced |
| Jan 1, 2023 | $46M Series B | Lorence KIM | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, OrbiMed, SR ONE, Third Rock Ventures, Lilly Asia Ventures, Sirona Capital | Announced |
| Sep 1, 2021 | $75M Series B | OrbiMed, SR ONE | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, Lilly Asia Ventures, Sirona Capital | Announced |
ADARx Pharmaceuticals is a clinical-stage biotechnology company headquartered in San Diego, California, founded in 2019, focused on developing next-generation RNA therapeutics to treat genetic, cardiometabolic, central nervous system, complement-mediated, cardiovascular, and metabolic diseases.[1][3][4] The company builds a proprietary RNA targeting platform featuring oligonucleotides for inhibition, degradation, and editing, paired with novel delivery technologies, serving patients with serious unmet needs in rare and common diseases through a diverse clinical-stage pipeline including ADX-324 (Phase 2 for Hereditary Angioedema), ADX-038 (Phase 2 for Paroxysmal Nocturnal Hemoglobinuria), and ADX-850 (Phase 1 for Essential Hypertension).[1][2][3] With $286M in total funding, including a $200M oversubscribed Series C led by investors like TCGX, ADARx demonstrates strong growth momentum, advancing multiple programs toward potentially transformative treatments with improved potency, precision, and durability.[1]
ADARx Pharmaceuticals emerged in 2019 from breakthroughs in RNA science, building on the 2006 Nobel Prize-winning discovery of RNA interference (RNAi) by Dr. Andrew Fire and Dr. Craig Mello, which unlocked gene-silencing mechanisms.[1][5] Led by President and CEO Zhen Li and CFO Ajim Tamboli, the company was founded to harness endogenous enzymes like ADAR for precise mRNA base editing, targeting single-point mutations to restore functional proteins.[2][6] Early traction came from developing a versatile RNA platform, culminating in significant funding milestones like the recent $200M Series C, supported by a board including experts such as Lorence Kim, Simeon J. George, and Carl L. Gordon, fueling rapid pipeline expansion into clinical stages.[1][6]
ADARx stands out in RNA therapeutics through proprietary technologies emphasizing precision and versatility:
ADARx rides the explosive growth of RNA therapeutics, amplified by RNAi pioneers' foundational work and recent successes like mRNA vaccines, positioning it to disrupt treatments for hard-to-drug diseases amid rising demand for precision genetic medicines.[3][5] Timing is ideal with advancing clinical data in complement-mediated (e.g., Hereditary Angioedema) and cardiometabolic areas, fueled by market forces like aging populations, genetic testing proliferation, and investor enthusiasm—evident in its $200M Series C amid a biotech funding resurgence.[1][2] ADARx influences the ecosystem by pioneering endogenous enzyme-based editing (e.g., ADAR-mediated), potentially expanding RNA's reach beyond silencing to correction, inspiring competitors and collaborators in biotech hubs like San Diego.[1][4][5]
ADARx is primed for milestone readouts from Phase 2 trials of ADX-324 and ADX-038 in 2026, potentially validating its platform and unlocking further funding or partnerships, while preclinical assets like RNA editing for Alpha-1 Antitrypsin Deficiency advance toward clinic.[2][3] Trends like AI-driven drug design and next-gen delivery will accelerate its pipeline, evolving its role from innovator to leader in durable RNA medicines for chronic diseases. As a biotech trailblazer turning cutting-edge RNA science into life-saving therapeutics, ADARx exemplifies how precision platforms can redefine patient outcomes in an era of genetic medicine.[1][5]
ADARx Pharmaceuticals has raised $321.0M in total across 3 funding rounds.
ADARx Pharmaceuticals's investors include Ricky Sun, Chen Yu, Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One, Third Rock Ventures, Ascenta Capital, BlackRock, Commodore Capital, Cormorant Asset Management.